Companies
RNS
Signals
Macro
Research
Indices
Ticker TV
Events
Commodities
Currencies
Footer menu
Search...
⌘K
Open sidebar
Developer Portal
News
Services
Coiled Therapeutics PLC (COIL) RNS Announcements | Ticker
/
Equities
/
AIMX
/
COIL
/
RNS
Secondary share class.
The ordinary shares trade as
ROQ
(Roquefort Therapeutics PLC). Director, financial and RNS data shown here are for the issuer.
Overview
Share Price
Financials
RNS
Trades
Short Interest
Directors
Holdings
Coiled Therapeutics PLC RNS
/
Equities
/
AIMX
/
COIL
/
RNS
Secondary share class.
The ordinary shares trade as
ROQ
(Roquefort Therapeutics PLC). Director, financial and RNS data shown here are for the issuer.
Overview
Share Price
Financials
RNS
Trades
Short Interest
Directors
Holdings
Coiled Therapeutics PLC RNS
Add to watchlist
Date
Time
Date
Title
Title
(filtered)
10/03/25
07:30:00
10 Mar 2025
Board Changes
Board Changes
10/03/25
07:00:11
10 Mar 2025
Proposed Sale of Oncogeni Ltd
Proposed Sale of Oncogeni Ltd
04/03/25
07:00:10
4 Mar 2025
Update on Sale of Lyramid
Update on Sale of Lyramid
04/02/25
10:58:22
4 Feb 2025
Director/PDMR Shareholding
Director/PDMR Shareholding
03/02/25
07:00:07
3 Feb 2025
Share Purchase Agreement Signed - Sale of Lyramid
Share Purchase Agreement Signed - Sale of Lyramid
02/01/25
07:00:06
2 Jan 2025
Proposed Sale of Midkine Portfolio
Proposed Sale of Midkine Portfolio
04/12/24
16:00:00
4 Dec 2024
Director Share Distribution
Director Share Distribution
07/11/24
07:00:05
7 Nov 2024
Conversion of Convertible Loan Notes
Conversion of Convertible Loan Notes
06/11/24
07:00:08
6 Nov 2024
STAT-6 siRNA Presentation
STAT-6 siRNA Presentation
27/09/24
07:00:01
27 Sept 2024
Interim Results to 30 June 2024
Interim Results to 30 June 2024
23/09/24
07:00:07
23 Sept 2024
Grant of Japan MK Cell Patent
Grant of Japan MK Cell Patent
19/09/24
07:00:02
19 Sept 2024
STAT-6 siRNA Demonstrates Efficacy in Immunology
STAT-6 siRNA Demonstrates Efficacy in Immunology
02/09/24
07:00:08
2 Sept 2024
Grant of MK Cell Patent & Licencing Update
Grant of MK Cell Patent & Licencing Update
27/06/24
12:46:12
27 Jun 2024
Results of AGM
Results of AGM
20/06/24
07:00:10
20 Jun 2024
Appointment of Broker
Appointment of Broker
04/06/24
07:00:09
4 Jun 2024
Notice of Annual General Meeting
Notice of Annual General Meeting
23/05/24
07:05:00
23 May 2024
Issue of Convertible Loan Notes & Board Changes
Issue of Convertible Loan Notes & Board Changes
23/05/24
07:00:15
23 May 2024
Midkine Antibody Licencing Deal
Midkine Antibody Licencing Deal
26/04/24
07:00:10
26 Apr 2024
Annual Report & Financial Statements - 31 Dec 2023
Annual Report & Financial Statements - 31 Dec 2023
05/04/24
07:00:08
5 Apr 2024
Response to Share Price Movement
Response to Share Price Movement
11/03/24
07:00:04
11 Mar 2024
Positive Results: Midkine mRNA and STAT-6 siRNA
Positive Results: Midkine mRNA and STAT-6 siRNA
06/02/24
07:00:03
6 Feb 2024
Operations Update
Operations Update
24/11/23
07:00:09
24 Nov 2023
Change of Auditor
Change of Auditor
06/11/23
07:00:13
6 Nov 2023
Significant Mesodermal Killer Cell Milestone
Significant Mesodermal Killer Cell Milestone
27/09/23
07:00:06
27 Sept 2023
Interim Results to 30 June 2023
Interim Results to 30 June 2023
22/09/23
11:42:40
22 Sept 2023
Investor Presentation via Investor Meet Company
Investor Presentation via Investor Meet Company
14/08/23
07:00:04
14 Aug 2023
Expansion of Patent Portfolio
Expansion of Patent Portfolio
07/08/23
07:00:05
7 Aug 2023
Development of New Novel siRNA Therapeutics
Development of New Novel siRNA Therapeutics
02/08/23
07:00:07
2 Aug 2023
Director/PDMR Shareholding
Director/PDMR Shareholding
12/07/23
10:27:25
12 Jul 2023
Director/PDMR Shareholding
Director/PDMR Shareholding
29/06/23
10:05:01
29 Jun 2023
Results of AGM
Results of AGM
29/06/23
07:00:02
29 Jun 2023
AGM Statement
AGM Statement
27/06/23
07:00:05
27 Jun 2023
Investor Presentation via Investor Meet Company
Investor Presentation via Investor Meet Company
26/06/23
14:41:29
26 Jun 2023
Director/PDMR Shareholding
Director/PDMR Shareholding
26/06/23
10:36:26
26 Jun 2023
Director/PDMR Shareholding
Director/PDMR Shareholding
26/06/23
10:00:10
26 Jun 2023
Director/PDMR Shareholding
Director/PDMR Shareholding
22/06/23
07:00:08
22 Jun 2023
RNA Medicine Shows In Vitro Anti-Cancer Efficacy
RNA Medicine Shows In Vitro Anti-Cancer Efficacy
19/06/23
07:00:04
19 Jun 2023
Antibody Program Results & Orphan Drug Indication
Antibody Program Results & Orphan Drug Indication
13/06/23
07:00:12
13 Jun 2023
Anti-Cancer MDK mRNA - Positive in vitro Results
Anti-Cancer MDK mRNA - Positive in vitro Results
07/06/23
10:11:46
7 Jun 2023
Restoration of Trading
Restoration of Trading
06/06/23
07:00:08
6 Jun 2023
Notice of Annual General Meeting
Notice of Annual General Meeting
05/06/23
07:00:07
5 Jun 2023
Annual Report & Financial Statements - 31 Dec 2022
Annual Report & Financial Statements - 31 Dec 2022
02/05/23
07:56:14
2 May 2023
Suspension of Trading Pending 2022 Annual Report
Suspension of Trading Pending 2022 Annual Report
02/05/23
07:30:02
2 May 2023
Suspension - Roquefort Therapeutics plc
Suspension - Roquefort Therapeutics plc
13/03/23
07:30:04
13 Mar 2023
Confirmation of No Exposure to Silicon Valley Bank
Confirmation of No Exposure to Silicon Valley Bank
08/03/23
07:00:06
8 Mar 2023
Creation of New Novel Family of mRNA Therapeutics
Creation of New Novel Family of mRNA Therapeutics
06/03/23
07:00:02
6 Mar 2023
Formation of Scientific Advisory Board
Formation of Scientific Advisory Board
01/03/23
07:00:12
1 Mar 2023
Company Presentation
Company Presentation
21/02/23
07:00:08
21 Feb 2023
Investor Presentation
Investor Presentation
20/02/23
07:00:03
20 Feb 2023
Randox Licence and Royalty Agreement
Randox Licence and Royalty Agreement
Showing 51–100 of 173 announcements
Previous
1
2
3
4
Next
Date
Time
Date
Title
Title
(filtered)
10/03/25
07:30:00
10 Mar 2025
Board Changes
Board Changes
10/03/25
07:00:11
10 Mar 2025
Proposed Sale of Oncogeni Ltd
Proposed Sale of Oncogeni Ltd
04/03/25
07:00:10
4 Mar 2025
Update on Sale of Lyramid
Update on Sale of Lyramid
04/02/25
10:58:22
4 Feb 2025
Director/PDMR Shareholding
Director/PDMR Shareholding
03/02/25
07:00:07
3 Feb 2025
Share Purchase Agreement Signed - Sale of Lyramid
Share Purchase Agreement Signed - Sale of Lyramid
02/01/25
07:00:06
2 Jan 2025
Proposed Sale of Midkine Portfolio
Proposed Sale of Midkine Portfolio
04/12/24
16:00:00
4 Dec 2024
Director Share Distribution
Director Share Distribution
07/11/24
07:00:05
7 Nov 2024
Conversion of Convertible Loan Notes
Conversion of Convertible Loan Notes
06/11/24
07:00:08
6 Nov 2024
STAT-6 siRNA Presentation
STAT-6 siRNA Presentation
27/09/24
07:00:01
27 Sept 2024
Interim Results to 30 June 2024
Interim Results to 30 June 2024
23/09/24
07:00:07
23 Sept 2024
Grant of Japan MK Cell Patent
Grant of Japan MK Cell Patent
19/09/24
07:00:02
19 Sept 2024
STAT-6 siRNA Demonstrates Efficacy in Immunology
STAT-6 siRNA Demonstrates Efficacy in Immunology
02/09/24
07:00:08
2 Sept 2024
Grant of MK Cell Patent & Licencing Update
Grant of MK Cell Patent & Licencing Update
27/06/24
12:46:12
27 Jun 2024
Results of AGM
Results of AGM
20/06/24
07:00:10
20 Jun 2024
Appointment of Broker
Appointment of Broker
04/06/24
07:00:09
4 Jun 2024
Notice of Annual General Meeting
Notice of Annual General Meeting
23/05/24
07:05:00
23 May 2024
Issue of Convertible Loan Notes & Board Changes
Issue of Convertible Loan Notes & Board Changes
23/05/24
07:00:15
23 May 2024
Midkine Antibody Licencing Deal
Midkine Antibody Licencing Deal
26/04/24
07:00:10
26 Apr 2024
Annual Report & Financial Statements - 31 Dec 2023
Annual Report & Financial Statements - 31 Dec 2023
05/04/24
07:00:08
5 Apr 2024
Response to Share Price Movement
Response to Share Price Movement
11/03/24
07:00:04
11 Mar 2024
Positive Results: Midkine mRNA and STAT-6 siRNA
Positive Results: Midkine mRNA and STAT-6 siRNA
06/02/24
07:00:03
6 Feb 2024
Operations Update
Operations Update
24/11/23
07:00:09
24 Nov 2023
Change of Auditor
Change of Auditor
06/11/23
07:00:13
6 Nov 2023
Significant Mesodermal Killer Cell Milestone
Significant Mesodermal Killer Cell Milestone
27/09/23
07:00:06
27 Sept 2023
Interim Results to 30 June 2023
Interim Results to 30 June 2023
22/09/23
11:42:40
22 Sept 2023
Investor Presentation via Investor Meet Company
Investor Presentation via Investor Meet Company
14/08/23
07:00:04
14 Aug 2023
Expansion of Patent Portfolio
Expansion of Patent Portfolio
07/08/23
07:00:05
7 Aug 2023
Development of New Novel siRNA Therapeutics
Development of New Novel siRNA Therapeutics
02/08/23
07:00:07
2 Aug 2023
Director/PDMR Shareholding
Director/PDMR Shareholding
12/07/23
10:27:25
12 Jul 2023
Director/PDMR Shareholding
Director/PDMR Shareholding
29/06/23
10:05:01
29 Jun 2023
Results of AGM
Results of AGM
29/06/23
07:00:02
29 Jun 2023
AGM Statement
AGM Statement
27/06/23
07:00:05
27 Jun 2023
Investor Presentation via Investor Meet Company
Investor Presentation via Investor Meet Company
26/06/23
14:41:29
26 Jun 2023
Director/PDMR Shareholding
Director/PDMR Shareholding
26/06/23
10:36:26
26 Jun 2023
Director/PDMR Shareholding
Director/PDMR Shareholding
26/06/23
10:00:10
26 Jun 2023
Director/PDMR Shareholding
Director/PDMR Shareholding
22/06/23
07:00:08
22 Jun 2023
RNA Medicine Shows In Vitro Anti-Cancer Efficacy
RNA Medicine Shows In Vitro Anti-Cancer Efficacy
19/06/23
07:00:04
19 Jun 2023
Antibody Program Results & Orphan Drug Indication
Antibody Program Results & Orphan Drug Indication
13/06/23
07:00:12
13 Jun 2023
Anti-Cancer MDK mRNA - Positive in vitro Results
Anti-Cancer MDK mRNA - Positive in vitro Results
07/06/23
10:11:46
7 Jun 2023
Restoration of Trading
Restoration of Trading
06/06/23
07:00:08
6 Jun 2023
Notice of Annual General Meeting
Notice of Annual General Meeting
05/06/23
07:00:07
5 Jun 2023
Annual Report & Financial Statements - 31 Dec 2022
Annual Report & Financial Statements - 31 Dec 2022
02/05/23
07:56:14
2 May 2023
Suspension of Trading Pending 2022 Annual Report
Suspension of Trading Pending 2022 Annual Report
02/05/23
07:30:02
2 May 2023
Suspension - Roquefort Therapeutics plc
Suspension - Roquefort Therapeutics plc
13/03/23
07:30:04
13 Mar 2023
Confirmation of No Exposure to Silicon Valley Bank
Confirmation of No Exposure to Silicon Valley Bank
08/03/23
07:00:06
8 Mar 2023
Creation of New Novel Family of mRNA Therapeutics
Creation of New Novel Family of mRNA Therapeutics
06/03/23
07:00:02
6 Mar 2023
Formation of Scientific Advisory Board
Formation of Scientific Advisory Board
01/03/23
07:00:12
1 Mar 2023
Company Presentation
Company Presentation
21/02/23
07:00:08
21 Feb 2023
Investor Presentation
Investor Presentation
20/02/23
07:00:03
20 Feb 2023
Randox Licence and Royalty Agreement
Randox Licence and Royalty Agreement
Showing 51–100 of 173 announcements
Previous
1
2
3
4
Next
